U.S. Residential REITs Stock News

NYSE:TWO
NYSE:TWOMortgage REITs

Two Harbors Dividend Tax Clarification And Valuation Gap For 2025

Two Harbors Investment, NYSE:TWO, has released tax treatment details for its 2025 common and preferred dividend distributions. The company stated that no portion of these 2025 distributions is expected to be classified as excess inclusion income. This clarification is intended to guide shareholders as they prepare tax reporting for the 2025 calendar year. For current holders of NYSE:TWO, the update comes with the stock recently trading at $11.47 and showing a mix of short term volatility...
NYSE:CFR
NYSE:CFRBanks

Cullen/Frost Bankers (CFR) Net Interest Margin Holds At 3.66% Challenging Bearish Narratives

Cullen/Frost Bankers (CFR) has just wrapped up FY 2025 with fourth quarter revenue of US$569.6 million and basic EPS of US$2.59, alongside net income of US$164.6 million and a reported net interest margin of 3.66%. Over the past few quarters the company has seen revenue move from US$520.2 million and EPS of US$2.37 in Q4 2024 to US$569.6 million and US$2.59 in Q4 2025. Trailing twelve month EPS stands at US$10.02 on revenue of about US$2.2 billion, and the current focus is on how durable...
NasdaqGS:NAVI
NasdaqGS:NAVIConsumer Finance

Is It Time To Reassess Navient (NAVI) After Recent Share Price Slide

If you are wondering whether Navient is priced attractively right now, the recent share moves and current valuation metrics give you quite a bit to think about. The stock recently closed at US$9.81, with returns of an 18.8% decline over 7 days, a 24.5% decline over 30 days, a 23.2% decline year to date and a 24.7% decline over the past year, alongside a 41.1% decline over 3 years and a 3.2% decline over 5 years. These moves have been unfolding against a backdrop of ongoing market attention...
NYSE:OGN
NYSE:OGNPharmaceuticals

Organon Draws Sun Offer As NEXPLANON Decision Reframes Value Debate

Sun Pharmaceutical has submitted a nonbinding offer to acquire Organon (NYSE:OGN). Organon recently received FDA approval for extended duration use of NEXPLANON with a new REMS safety program. These developments affect Organon’s women’s health portfolio and potential ownership structure. Organon, trading at $8.54, is coming into focus as both a deal target and a women’s health player with a newly approved product label. The share price is up 19.1% over the past 30 days and 18.0% year to...
NYSE:TTI
NYSE:TTIEnergy Services

Assessing TETRA Technologies (TTI) Valuation After Strong Recent Share Price Momentum

TETRA Technologies (TTI) has drawn fresh attention after a strong share price move over the past month and the past three months, prompting investors to reassess its valuation and recent financial profile. See our latest analysis for TETRA Technologies. That recent share price run, including a 21.66% 30 day share price return and 61.47% 90 day share price return to US$11.40, sits alongside a very strong 1 year total shareholder return of 174.70% and a 5 year total shareholder return above 4x...
NasdaqGS:VIAV
NasdaqGS:VIAVCommunications

Viavi Solutions (VIAV) Margin Worsening To Q2 Loss Challenges High Growth Narratives

Viavi Solutions (VIAV) has just posted Q2 2026 results with revenue of US$369.3 million and a basic EPS loss of US$0.21, while trailing twelve month figures show revenue of US$1.2 billion and a basic EPS loss of US$0.19. Over recent quarters, the company has seen revenue move from US$270.8 million in Q2 2025 to US$369.3 million in Q2 2026, with EPS shifting from a profit of US$0.04 to a loss of US$0.21 as margins compressed. See our full analysis for Viavi Solutions. With the latest numbers...
NasdaqGS:SILC
NasdaqGS:SILCCommunications

Silicom (SILC) Quarterly Losses Persist Challenging Bullish Profitability Narratives

Silicom (SILC) closed FY 2025 with Q4 revenue of US$16.9 million and a basic EPS loss of US$0.44, alongside net income excluding extra items of a US$2.5 million loss, putting another loss-making quarter on the scoreboard. Over recent periods the company has seen quarterly revenue move from US$14.5 million in Q4 2024 through US$14.4 million in Q1 2025, US$15.0 million in Q2, and US$15.6 million in Q3. Quarterly basic EPS stayed in loss territory, ranging from a US$1.05 loss per share in Q4...
NasdaqGM:VERA
NasdaqGM:VERABiotechs

Vera Therapeutics Adds CCO As Atacicept Advances And Valuation Gap Persists

Vera Therapeutics (NasdaqGM:VERA) has appointed Matt Skelton as Chief Commercial Officer. The move comes as the company prepares for potential commercialization of its lead drug, atacicept, for IgA nephropathy. Atacicept has received Breakthrough Therapy Designation and Priority Review from the FDA. Vera Therapeutics focuses on therapies for serious immunologic diseases, with atacicept as its lead asset in IgA nephropathy. The addition of a Chief Commercial Officer signals that management...
NasdaqGS:ETOR
NasdaqGS:ETORCapital Markets

Could New PFOF Rules Quietly Reshape eToro Group’s (ETOR) Core Competitive Edge?

Recent industry attention on eToro Group has focused on how upcoming regulatory changes, including MiFID II amendments, DORA enforcement and a Payment-for-Order-Flow ban, are set to redefine operating standards for digital brokerage platforms. These shifts are expected to raise the bar on transparency, resilience and data connectivity, offering larger players such as eToro an opportunity to deepen user engagement and reinforce trust through stronger compliance and richer account aggregation...